NCT00368875View on ClinicalTrials.gov

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Male Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DRUG

vorinostat

Given orally

DRUG

paclitaxel

Given IV

BIOLOGICAL

bevacizumab

Given IV

Trial Locations (1)

10467-2490

Montefiore Medical Center, The Bronx

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00368875 - Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter